Iron Metallodrugs: Stability, Redox Activity and Toxicity against Artemia salina
Open Access
- 7 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (4) , e0121997
Abstract
Iron metallodrugs comprise mineral supplements, anti-hypertensive agents and, more recently, magnetic nanomaterials, with both therapeutic and diagnostic roles. As biologically-active metal compounds, concern has been raised regarding the impact of these compounds when emitted to the environment and associated ecotoxicological effects for the fauna. In this work we assessed the relative stability of several iron compounds (supplements based on glucoheptonate, dextran or glycinate, as well as 3,5,5-trimethylhexanoyl (TMH) derivatives of ferrocene) against high affinity models of biological binding, calcein and aprotransferrin, via a fluorimetric method. Also, the redox-activity of each compound was determined in a physiologically relevant medium. Toxicity toward Artemia salina at different developmental stages was measured, as well as the amount of lipid peroxidation. Our results show that polymer-coated iron metallodrugs are stable, non-redox-active and non-toxic at the concentrations studied (up to 300 µM). However, TMH derivatives of ferrocene were less stable and more redox-active than the parent compound, and TMH-ferrocene displayed toxicity and lipid peroxidation to A. salina, unlike the other compounds. Our results indicate that iron metallodrugs based on polymer coating do not present direct toxicity at low levels of emission; however other iron species (eg. metallocenes), may be deleterious for aquatic organisms. We suggest that ecotoxicity depends more on metal speciation than on the total amount of metal present in the metallodrugs. Future studies with discarded metallodrugs should consider the chemical speciation of the metal present in the composition of the drug.Keywords
This publication has 32 references indexed in Scilit:
- Silica-encapsulated magnetic nanoparticles: Enzyme immobilization and cytotoxic studyInternational Journal of Biological Macromolecules, 2012
- Ferrocenyl compounds possessing protected phenol and thiophenol groups: Synthesis, X-ray structure, and in vitro biological effects against breast cancerJournal of Organometallic Chemistry, 2008
- Oxidative stress and damage in liver, but not in brain, of fischer 344 rats subjected to dietary iron supplementation with lipid‐soluble [(3,5,5‐trimethylhexanoyl)ferrocene]Journal of Biochemical and Molecular Toxicology, 2007
- Using coordination chemistry to design new medicinesCoordination Chemistry Reviews, 2007
- Household disposal of pharmaceuticals and perception of risk to the environmentEnvironmental Toxicology and Pharmacology, 2006
- Relevance, essentiality and toxicity of trace elements in human healthMolecular Aspects of Medicine, 2005
- Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin‐bound iron in dialysis patientsEuropean Journal of Clinical Investigation, 2002
- The Lipophilic Iron Compound TMH-Ferrocene [(3,5,5-Trimethylhexanoyl)ferrocene] Increases Iron Concentrations, Neuronal L-Ferritin, and Heme Oxygenase in Brains of BALB/c MiceBiological Trace Element Research, 2002
- Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene−Chloroquine AnalogueJournal of Medicinal Chemistry, 1997
- Non-transferrin-bound-iron in serum and low-molecular-weight-iron in the liver of dietary iron-loaded ratsInternational Journal of Biochemistry, 1993